Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a …,

The CALVID-1 study is a prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial in approximately 230 patients with …, The CALVID-1 study is a prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial in approximately 230 patients with …, Read More

Scroll to Top